Baseline characteristics
| SLE group | Non-SLE group | |
|---|---|---|
| n=130 | n=132 | |
| Age (years) | 68.8 (8.6) | 69.1 (9.0) |
| Men | 104 (80.0%) | 92 (69.7%) |
| Body mass index (kg/m2) | 23.5 (3.0) | 23.6 (2.9) |
| Performance status | ||
| 0 | 128 (98.5%) | 128 (97.0%) |
| 1 | 2 (1.5%) | 4 (3.0%) |
| History of gastric ulcer | 15 (11.5%) | 12 (9.1%) |
| Hypertension | 59 (45.4%) | 53 (40.2%) |
| Hyperlipidaemia | 31 (23.8%) | 21 (15.9%) |
| Diabetes mellitus | 16 (12.3%) | 12 (9.1%) |
| Longitudinal location* | ||
| Body | 80 (61.5%) | 76 (57.6%) |
| Antrum | 50 (38.5%) | 56 (42.4%) |
| Cross-sectional location | ||
| Anterior | 27 (20.8%) | 26 (20.0%) |
| Posterior | 24 (18.5%) | 24 (18.2%) |
| Lesser curvature | 55 (42.3%) | 56 (42.4%) |
| Greater curvature | 24 (18.5%) | 26 (20.0%) |
| Tumour size (mm) | 14.7 (10.4) | 14.5 (9.2) |
| Tumour size >20 mm* | 18 (13.8%) | 21 (15.9%) |
| Ulcerative finding* | 15 (11.5%) | 13 (9.8%) |
| Macroscopic type | ||
| Protruding | 33 (25.4%) | 38 (28.8%) |
| Flat/depressed | 85 (65.4%) | 89 (67.4%) |
| Combined | 12 (9.2%) | 5 (3.8%) |
| Residual tumour | 2 (1.5%) | 2 (1.5%) |
| Histological depth | ||
| Mucosal | 112 (86.2%) | 115 (87.1%) |
| Submucosal or deeper | 18 (13.8%) | 17 (12.9%) |
| Histological type | ||
| Intestinal | 120 (92.3%) | 119 (90.2%) |
| Diffuse | 5 (3.8%) | 7 (5.3%) |
| Benign | 5 (3.8%) | 6 (4.5%) |
| Institution* | ||
| A | 30 (23.1%) | 30 (22.7%) |
| B | 42 (32.3%) | 42 (31.8%) |
| C | 36 (27.7%) | 36 (27.3%) |
| D | 12 (9.2%) | 11 (8.3%) |
| E | 10 (7.7%) | 13 (9.8%) |
| Anaesthesia method | ||
| Intravenous | 128 (98.5%) | 131 (99.2%) |
| General | 2 (1.5%) | 1 (0.8%) |
| Cutting device | ||
| Needle-tip type† | 31 (23.8%) | 28 (21.2%) |
| Insulated-tip type‡ | 99 (76.2%) | 104 (78.8%) |
| Submucosal injection solution | ||
| With sodium hyaluronate | 101 (77.7%) | 99 (75.0%) |
| With epinephrine | 97 (74.6%) | 103 (78.0%) |
| Coagulating device | ||
| Radial jaw hot biopsy forceps | 68 (52.3%) | 63 (47.7%) |
| Coagrasper | 32 (24.6%) | 40 (30.3%) |
| Pentax haemostatic forceps | 30 (23.1%) | 29 (22.0%) |
| Time of ESD (min) | 86.3 (50.7) | 81.9 (46.5) |
| Time of ESD >120 min | 25 (19.2%) | 16 (12.1%) |
| Time of prophylactic coagulation (min) | 9.1 (5.3) | 8.7 (4.8) |
| Time of prophylactic coagulation >9 min | 59 (45.4%) | 57 (43.2%) |
| Operator experience | ||
| <30 cases | 32 (24.6%) | 35 (26.5%) |
| 31–50 cases | 18 (13.8%) | 23 (17.4%) |
| 51–100 cases | 41 (31.5%) | 36 (27.3%) |
| >100 cases | 39 (30.0%) | 38 (28.8%) |
| Specimen size (mm) | 39.7 (16.0) | 40.0 (14.5) |
| Specimen size >40 mm | 50 (38.5%) | 52 (39.4%) |
| En bloc resection | 130 (100%) | 132 (100%) |
| Curative resection | 110 (84.6%) | 113 (85.6%) |
Data are the mean (SD) or number (%).
*For stratification factor.
†Including dual knife.
‡Including insulation-tipped knife-2, SAFE knife and clutch cutter.
ESD, endoscopic submucosal dissection; SLE, second-look endoscopy.